People: Brainstorm Cell Therapeutics Inc. (BCLI.OB)

BCLI.OB on OTC BB

0.32USD
9 Feb 2010
Price Change (% chg)

$0.04 (+12.07%)
Prev Close
$0.32
Open
--
Day's High
$0.35
Day's Low
$0.30
Volume
557,798
Avg. Vol
153,325
52-wk High
$0.49
52-wk Low
$0.05

view people for:

Summary

Name Age Since Current Position
Efrati, Abraham 59 2009 Chief Executive Officer, Director
Lebovits, Chaim 38 2007 President
Stolick, David 43 2005 Chief Financial Officer
Arbel, Irit 49 2004 Director
Javitt, Jonathan 52 2007 Director
Lion, Moshe 48 2007 Director
Shorr, Robert 55 2005 Director
Taub, Malcolm 63 2009 Director
» Insider Trading

Biographies

Name Description
Efrati, Abraham Mr. Abraham (Rami) Efrati joined Brainstorm Cell Therapeutics Inc. in October 2007 as Chief Executive Officer. On April 13, 2009, Mr. Efrati was elected to the Board of Directors. In 2004, Mr. Efrati founded, and is currently the Chief Executive Officer of, Pro-Int Ltd., a private company. In 2005, Mr. Efrati co-founded, and is currently the Chief Executive Officer of, TeleFlight Technologies Ltd., a technology company specializing in research and development of micro electronics solutions mainly oriented for unmanned systems. From 1997 until 2004, Mr. Efrati served as the Vice President, Sales, Business Development and Marketing for the government project division of NICE-Systems Ltd., a provider of solutions that capture, manage and analyze unstructured multimedia content and transactional data enabling companies and public organizations to enhance business and operational performance, address security threats and behave proactively.
Lebovits, Chaim Mr. Chaim Lebovits joined Brainstorm Cell Therapeutics Inc. in July 2007 as President. Mr. Lebovits controls ACC Holdings, a holding company which controls three subsidiaries: (i) C&L Natural Resources; (ii) ACC Resources; and (iii) ACCBT. C&L Natural Resources focuses on oil production in West Africa and operates an oil and gas field with proven reserves of 20 million barrels of oil and an option to discover up to an additional 100 million barrels of oil. ACC Resources holds 10 permits for gold exploration in Burkina Faso. ACCBT focuses on new and emerging biotechnologies. Mr. Lebovits has been at the forefront of mining and natural resource management in the African region for close to a decade. Mr. Lebovits serves as the President and as a director of Dominion Minerals Corp., a company that trades on the OTC BB.
Stolick, David Mr. David Stolick joined Brainstorm Cell Therapeutics Inc. in February 2005 as Chief Financial Officer. From January 1995 to April 2005, Mr. Stolick was Corporate Controller of M-Systems Flash Disk Pioneers Ltd., a NASDAQ listed company. In 1994, he served as Deputy Controller of Electronics Line Ltd., an Israeli publicly traded company, and from 1991 until 1994 he was Audit Manager at Goldstein, Sabbo, and Tebet Accountants. Mr. Stolick holds a B.A. in Economics and Accounting from Ben-Gurion University. He has been qualified as a certified accountant in Israel since 1993.
Arbel, Irit Dr. Irit Arbel joined Brainstorm Cell Therapeutics Inc. in May 2004 as a Director and as President. She served as President until she resigned in November 2004. Dr. Arbel was President and CEO of Pluristem Life Systems, Inc. from 2002 to June 2004, and was Israeli Sales Manager of Merck, Sharp & Dohme from 1998 to 2002. From 1995 to 1997, Dr. Arbel served as the head of research for Hadassa-Ein Karem Hospital in Jerusalem. Dr. Arbel specialized in the use of pharmaceuticals for neurology, ophthalmology and dermatology treatments. Dr. Arbel earned her Post Doctorate degree in 1997 in Neurobiology, after performing research in the area of Multiple Sclerosis. Dr. Arbel also holds a Chemical Engineering degree from the Technion, Israel's Institute of Technology.
Javitt, Jonathan Dr. Jonathan C. Javitt joined Brainstorm Cell Therapeutics Inc. as a Director in August 2007. Dr. Javitt is a physician with a background in information technology, health economics, and public health. Since 2001, Dr. Javitt has served as a Senior Fellow of the Potomac Institute for Policy Studies, and since 1998 has also served as Chairman and CEO of Health Directions, LLC, an investment and consulting group that focuses on healthcare information technology and biotechnology. Dr. Javitt has been a founder of health information technology companies that have become part of Siemens, Inc., United Health Group, Inc., and Aetna, Inc. Currently, he serves as Managing Director for Health Care and Life Sciences of BTI, Inc. and is a Director of Flexscan, Inc. Since 1988, Dr. Javitt has also served as a Professor of Ophthalmology (adjunct) at the Johns Hopkins University. Dr. Javitt has considerable expertise and experience in the development of new drugs, having worked extensively over the past twenty years with Merck, Inc., Pfizer, Inc., Allergan, Inc., Alcon, Inc., OSI, Inc., and others in bringing new drugs and medical devices to the marketplace.
Lion, Moshe Mr. Moshe Lion joined Brainstorm Cell Therapeutics Inc. as a Director in July 2007. Since 1999, Mr. Lion has been a senior partner of Lion, Orlitzki and Partners, a member of Moore Stephens international partnership. Mr. Lion also serves as a director for Elbit Medical Imaging Ltd. Previously, Mr. Lion was Chairman of Israel Railways, Director of the Israel Council for Higher Education and the Wingate Institute for Physical Education, Director of Elscint Ltd., Director of Massad Bank and Director of Bank Tefahot. Prior to that, Mr. Lion served as Director General of the Israeli Prime Minister's Office as well as an economic advisor to the Israeli Prime Minister. He also served as the Head of the Bureau of the Israeli Prime Minister's Office. Mr. Lion holds a Bachelor of Arts degree in accounting and economics and a Master's Degree in Law (LL.M.) from Bar Ilan University.
Shorr, Robert Dr. Robert Shorr joined Brainstorm Cell Therapeutics Inc. as a Director in March 2005. Since 2000, Dr. Shorr has served as President and CEO of Cornerstone Pharmaceuticals, a bio technology company. Since 1998, he has also served as Director of Business Development at the State University of New York at the Stony Brook Center for Advanced Technology. From 1998 until 2002, Dr. Shorr was Vice-President of Science and Technology (CSO) of United Therapeutics, a NASDAQ listed company. He has served as trustee at the Tissue Engineering Charities, Imperial College, London since 1999. Prior to 1998 he held management positions at Enzon Inc., a NASDAQ listed company, and AT Biochem of which he was also founder. Dr. Shorr also served on the Board of Directors of Biological Delivery Systems Inc., a NASDAQ listed company. Dr. Shorr holds both a Ph.D. and a D.I.C. from the University of London, Imperial College of Science and Technology as well as a B.Sc. from the State University of New York.
Taub, Malcolm Mr. Malcolm Taub joined Brainstorm Cell Therapeutics Inc. as a Director in March 2009. Since 1995, Mr. Taub has been the Managing Member of Malcom S. Taub LLP, a law firm which practices in the area of commercial litigation, among other practice areas. Mr. Taub also works on art transactions, in the capacity of an attorney and consultant. My Taub has also served as a principal of a firm that provides consulting services to private companies going public in the United States. Mr. Taub has acted as a consultant to the New York Stock Exchange in its Market Surveillance Department. Mr. Taub acts as a Trustee of The Gateway Schools of New York and The Devereux Glenholme School in Washington, Connecticut. Mr. Taub has served as an adjunct professor at Long Island University, Manhattan Marymount College and New York University Real Estate Institute. Mr. Taub holds a B.A. degree from Brooklyn College and a J.D. degree from Brooklyn Law School. Mr. Taub serves on the Board of Directors of Safer Shot, Inc. (formerly known as Monumental Marketing Inc.), a company which trades on the Pink Sheets.

Basic Compensation

Name Fiscal Year Total
Efrati, Abraham 487,297
Lebovits, Chaim 59,342
Stolick, David 225,187
Arbel, Irit --
Javitt, Jonathan --
Lion, Moshe --
Shorr, Robert --
Taub, Malcolm --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Efrati, Abraham 0 0
Lebovits, Chaim 0 0
Stolick, David 0 0
Arbel, Irit 0 0
Javitt, Jonathan 0 0
Lion, Moshe 0 0
Shorr, Robert 0 0
Taub, Malcolm 0 0

Insider Trading

Name Shares Traded Price
ACCBT CORP 2,000,000 $0.18
» Full list on Insider Trading
view people for: